|
C12ORF11 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.03539998796975E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.70670000021467E-07 |
| Normal-vs-Stage2 |
3.394200E-02 |
| Normal-vs-Stage3 |
9.28834786861898E-12 |
| Normal-vs-Stage4 |
5.74950087539605E-11 |
| Stage1-vs-Stage2 |
1.785960E-01 |
| Stage1-vs-Stage3 |
1.458330E-03 |
| Stage1-vs-Stage4 |
3.644100E-03 |
| Stage2-vs-Stage3 |
1.423740E-03 |
| Stage2-vs-Stage4 |
1.958180E-03 |
| Stage3-vs-Stage4 |
6.625000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.62539998022271E-10 |
| Normal-vs-AfricanAmerican |
1.36749999990471E-07 |
| Normal-vs-Asian |
2.000400E-04 |
| Caucasian-vs-AfricanAmerican |
2.753400E-01 |
| Caucasian-vs-Asian |
2.945600E-01 |
| AfricanAmerican-vs-Asian |
6.921900E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.33370000043875E-07 |
| Normal-vs-Female |
1.21980003875422E-09 |
| Male-vs-Female |
6.874000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.65159999962772E-07 |
| Normal-vs-Age(41-60Yrs) |
5.32609956138685E-10 |
| Normal-vs-Age(61-80Yrs) |
3.38579999592525E-08 |
| Normal-vs-Age(81-100Yrs) |
2.45129999999483E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.568400E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.267440E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.319900E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.861000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.727600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.708200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.089610E-02 |
| Classical-VS-Follicular |
1.374410E-02 |
| Classical-VS-Other |
3.771200E-01 |
| Classical-VS-Normal |
1.50229999551499E-08 |
| Tall-VS-Follicular |
1.995440E-04 |
| Tall-VS-Other |
6.590400E-02 |
| Tall-VS-Normal |
1.82439996443406E-09 |
| Follicular-VS-Other |
9.194800E-01 |
| Follicular-VS-Normal |
1.259500E-02 |
| Other-VS-Normal |
3.697800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
6.75860000187711E-08 |
| Normal-vs-N1 |
3.40169999946127E-07 |
| N0-vs-N1 |
1.655200E-01 |
|
|
